Form 4: AnaptysBio Chief Legal Officer Reports Stock Transactions
SEC Form 4
Eric Loumeau, Chief Legal Officer of AnaptysBio, reports the acquisition and disposal of common stock and restricted stock units related to vesting and tax obligations.
Summary
- On January 3, 2025, Eric Loumeau, Chief Legal Officer of AnaptysBio, exercised restricted stock units (RSUs) to acquire 7,288 shares of common stock.
- He also disposed of 2,994 shares to cover tax withholding obligations at a price of $14.6 per share.
- Following these transactions, Loumeau directly owns 7,675 shares of common stock.
- On January 6, 2025, Loumeau exercised RSUs to acquire 5,545 shares of common stock.
- He also disposed of 2,217 shares to cover tax withholding obligations at a price of $15.3 per share.
- Following these transactions, Loumeau directly owns 11,003 shares of common stock.
- On January 7, 2025, Loumeau was granted 23,550 restricted stock units and options to purchase 67,000 shares.
- The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested.
Sentiment
Score: 5
Explanation: This Form 4 filing is a neutral event, simply reporting required insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The reporting person will continue to vest in RSUs and stock options in the future, subject to continued service with the Issuer.
Industry Context
This is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies. It provides transparency into the trading activities of key personnel.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency in insider trading.
- Similar filings are made by executives at comparable biotech companies like Amgen, Regeneron, and Gilead Sciences, reflecting their stock transactions.
- The vesting schedules and option grants are typical compensation components for executives in the biotechnology industry.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation mechanisms.
- Shareholders may view the transactions as a routine part of executive compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of earliest transaction: RSU exercise and tax-related disposal of shares. |
| 01/06/2025 | RSU exercise and tax-related disposal of shares. |
| 01/07/2025 | Grant date of additional RSUs and stock options. |
| 01/06/2035 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.